These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38205078)

  • 1. Development of PARP inhibitors in advanced prostate cancer.
    Bourlon MT; Valdez P; Castro E
    Ther Adv Med Oncol; 2024; 16():17588359231221337. PubMed ID: 38205078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
    Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
    Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?
    Garofoli M; Maiorano BA; Bruno G; Giordano G; Di Tullio P; Maselli FM; Landriscina M; Conteduca V
    Ther Adv Med Oncol; 2024; 16():17588359241258443. PubMed ID: 38887656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials.
    Panebianco M; Cereda V; D'Andrea MR
    Explor Target Antitumor Ther; 2024; 5(5):997-1010. PubMed ID: 39351435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    Adashek JJ; Jain RK; Zhang J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors alone or in combination for prostate cancer.
    Fenor de la Maza MD; Pérez Gracia JL; Miñana B; Castro E
    Ther Adv Urol; 2024; 16():17562872241272929. PubMed ID: 39184454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in metastatic prostate cancer.
    Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
    Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N
    Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    Nizialek E; Antonarakis ES
    Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.
    Giesen A; Baekelandt L; Devlies W; Devos G; Dumez H; Everaerts W; Claessens F; Joniau S
    Front Oncol; 2023; 13():1265812. PubMed ID: 37810962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.
    Zaman N; Kushwah AS; Badriprasad A; Chakraborty G
    Int Rev Cell Mol Biol; 2024; 389():257-301. PubMed ID: 39396849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors in prostate cancers, is it time for combinations?
    Teyssonneau D; Dariane C; Barret E; Beauval JB; Brureau L; Fiard G; Fromont G; Créhange G; Gauthé M; Ruffion A; Renard-Penna R; Mathieu R; Sargos P; Rouprêt M; Ploussard G; Roubaud G
    Ther Adv Med Oncol; 2024; 16():17588359241242959. PubMed ID: 38827177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    Ziadeh T; Kourie HR
    Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
    Wenzel M; Hoeh B; Koll F; Humke C; Fassl A; Reis H; Wild P; Steuber T; Graefen M; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
    BJU Int; 2025 Jan; 135(1):117-124. PubMed ID: 38982928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape.
    Al-Akhras A; Hage Chehade C; Narang A; Swami U
    Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.